… the hearts of old gave hands;
![]() | ![]() |
Formats:
|
||||
Copyright © 1999, The National Academy of Sciences Heart or hand? Unmasking the basis for specific Holt-Oram phenotypes *Molecular Cardiology Unit and Departments of †Medicine, ‡Cell Biology, and §Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030 ¶To whom reprint requests should be addressed at: Molecular
Cardiology Unit, One Baylor Plaza, Room 506C, Baylor College of
Medicine, Houston, TX 77030. e-mail: michaels/at/bcm.tmc.edu. See the article "Different TBX5 interactions in heart and limb defined by Holt–Oram syndrome mutations" on page 2919. This article has been cited by other articles in PMC.
But our new heraldry is hands, not hearts. —William Shakespeare, Othello A paramount challenge in developmental biology and
genetics is to provide explicit molecular explanations for the complex
processes that together comprise morphogenesis—not merely the
activation of tissue-specific differentiation programs, but also
broader phenomena, such as positional information along multiple axes,
orchestrated cell movements, and other aspects of pattern formation. In
vertebrates, steps toward the formation of a mature, multichambered
heart include the induction of cardiac precursors in lateral plate
mesoderm, their migration to the ventral midline to form a linear heart
tube, rightward looping (the first overt left-right asymmetry in the
embryo), and subsequent developmentally regulated events, including
chamber specialization, septation, and irreversible cell cycle exit
(1). Many genes affecting cardiac organogenesis have been identified in
recent years by saturation mutagenesis in flies and fish, fortuitous
insertions in mice, and targeted deletions in embryonic stem cells.
Congenital cardiac malformations are the most common form of heart
disease in childhood, occurring in ≈1% of live births and perhaps
10% of stillbirths (2, 3), yet a genetic basis for such defects in
humans is understood only rarely. The manuscript by Basson et
al. in this issue of the Proceedings (4) provides
surprising new insight into the variable phenotypes in Holt-Oram
syndrome, a disorder of heart and forelimb development caused by
mutations of the T-box transcription factor, TBX5. The Brachyury (T) gene, the prototype for this family, was
identified early in this century as a mutation affecting primitive
streak and notochord differentiation in mice, resulting in a short tail
phenotype when heterozygous and loss of posterior mesoderm formation
(trunk and tail) when homozygous (5–7). Positional cloning of the
Brachyury gene, isolation of Brachyury
orthologues in diverse other vertebrates, the similar phenotype
(no tail) in zebrafish lacking the gene, localization of
Brachyury protein to the cell nucleus, identification of a
palindromic Brachyury binding site, and proof that this
protein indeed can function as a transcription factor together comprise
a remarkable set of advances toward the transcriptional mechanisms
underlying mesoderm formation (5–7). Direct evidence for
Brachyury function is illustrated by its ability to trigger
ectopic mesoderm formation when over-expressed in Xenopus
embryos (8) and to disrupt mesoderm formation when engineered as a
dominant-negative protein in Xenopus or zebrafish, causing
axial phenotypes like those in Brachyury mutant mice (9).
The Drosophila protein optomer blind
(omb) was the first paralogue to be found, with similarity
to the N-terminal T domain for DNA-binding but departing from
Brachyury outside this domain. In mammals, the T-box family
presently encompasses at least 10 members, 5 of which are expressed in
the developing limbs including TBX5 (10). Two years ago, TBX5 was
identified as a gene for Holt-Oram syndrome (HOS1, OMIM 142900), a
human disorder of forelimb and heart development with autosomal
dominant inheritance that is seen in 1 per 100,000 live births (refs.
11 and 12; http://www.ncbi.nlm.nih.gov/omim). The skeletal
involvement varies but is typically bilateral, with the left side and
radial (thumb) defects predominating. Defects of the interatrial and
interventricular septa are the characteristic cardiac findings,
although other cardiac structural abnormalities and cardiac conduction
system disease also occur (refs. 11 and 12;
http://www.ncbi.nlm.nih.gov/omim). Linkage studies had mapped a
Holt-Oram syndrome gene to chromosome 12q2, genetic and physical
mapping refined the locus to an ≈1-centimorgan critical region, and
exon trapping revealed TBX5 as an expressed sequence from this region,
which otherwise contained no known genes (11, 12). In human embryos,
TBX5 was abundant in the early heart tube at 26 days of gestation and
later was expressed in the forelimbs and other sites (12). Most common
among the initially identified mutations were premature stop codons and
frame-shift mutations, which are expected to function as null alleles
(11, 12), with one missense mutation in the carboxyl terminus of the
predicted DNA-binding T domain (Arg237Gln) (4, 11). The current article by Basson et al. reports significant new
information—a second family with this exact missense mutation, a
second mutation affecting this residue (Arg237Trp), and a second
residue as the site for a mutation (Gly80Arg)—information that is made
intriguing by suggestive structure–function correlations. Gly80
resides near the amino terminus of the T-box: Based on the
crystallographic structure of Xenopus Brachyury protein
bound to a target DNA palindrome (13), the arginine substitution is
predicted to alter interaction with the major groove. The C-terminal
helix, by contrast, mediates sequence-specific recognition in the minor
groove, and the substitution of glutamine or tryptophan for Arg237
therefore is also expected to alter interactions of TBX5 with DNA. What
elevates the present study beyond “just” an astute extrapolation
from the Xbra crystal structure is the remarkable
concordance of Holt-Oram phenotypes with these specific missense
mutations, despite the varigated nature of this syndrome overall. For
null alleles, composite cardiac defects and severe skeletal
malformations both were frequent (57% and 65%, respectively). For
Gly80Arg, cardiac phenotypes were severe, but the skeletal involvement
was mild; for Arg237Gln and Arg237Trp, a reciprocal pattern was seen,
with severe skeletal malformations but only rare composite cardiac
defects. Thus, preferential involvement of heart versus limb occurs
predictably as the consequence of which residue is altered in the
DNA-binding T domain. The authors offer the logical speculation that
their findings may point to different target genes for TBX5 in these
two developmental pathways, perhaps involving different
protein–protein interactions. Such a model accounts for the diverse,
cell type-specific functions driven by certain other transcription
factors, including the MADS (MCM1, agamous, deficiens, serum response
factor) box proteins, serum response factor itself (14, 15), and
myocyte enhancer factor 2 (16, 17). In these instances, the domains for
binding DNA also confer essential protein-binding interactions;
however, whether this is also true for the T-box is unknown. A wealth of information implicates T-box proteins in organogenesis,
including recent evidence that TBX3 is the cause of ulnary-mammary
syndrome in humans (18) and that Tbx6 is required for posterior
paraxial mesoderm (19). Despite these advances, the identification of
genes that T-box proteins regulate directly has been elusive. One such
target, the homeobox gene, Bix1, recently was isolated by
using a combination of hormone-inducible Brachyury protein
and subtractive hybridization (20), a strategy that might well be
applied to other T-box proteins, including TBX5, or to comparisons
between wild-type and mutant TBX5. Insights reported in the present
study should give impetus to the quest for target genes controlled by
TBX5 as the necessary next step to map the pathways governed by this
protein in heart and hand morphogenesis. One further challenge is to
pinpoint which cell lineages are affected as the primary consequence,
an issue that could be addressed by conditional deletions in mice
(21–23). Other heart-hand syndromes exist that do not map to chromosome 12q2
(24). The concurrence of cardiac and limb malformations may be even
more general than supposed, with positional correlations seen between
specific malformations within the spectrum of possible defects (25).
This has been taken to suggest the likelihood of clinical mutations
that fall elsewhere in these developmental cascades controlling the
creation of hands and hearts (25). Footnotes A commentary on this article
begins on page 2919. References 1. Harvey, R. P. & Rosenthal, N. (1998) (Academic, New
York). 2. Hoffman J I. Pediatr Cardiol. 1995;16:155–165. [PubMed] 3. Hoffman J I. Pediatr Cardiol. 1995;16:103–113. [PubMed] 4. Basson C T, Huang T, Lin R C, Bachinsky D R, Weremowicz S, Vaglio A, Bruzzone R, Quadrelli R, Lerone M, Romeo G, et al. Proc Natl Acad Sci USA. 1999;96:2919–2924. [PubMed] 5. Kispert A, Koschorz B, Herrmann B G. EMBO J. 1995;14:4763–4772. [PubMed] 6. Smith J. Curr Opin Genet Dev. 1997;7:474–480. [PubMed] 7. Papaioannou V E, Silver L M. BioEssays. 1998;20:9–19. [PubMed] 8. Cunliffe V, Smith J C. Nature (London). 1992;358:427–430. [PubMed] 9. Conlon F L, Sedgwick S G, Weston K M, Smith J C. Development (Cambridge, UK). 1996;122:2427–2435. [PubMed] 10. Agulnik S I, Papaioannou V E, Silver L M. Genomics. 1998;51:68–75. [PubMed] 11. Basson C T, Bachinsky D R, Lin R C, Levi T, Elkins J A, Soults J, Grayzel D, Kroumpouzou E, Traill T A, Leblanc-Straceski J, et al. Nat Genet. 1997;15:411. 12. Li Q Y, Newbury-Ecob R A, Terrett J A, Wilson D I, Curtis A R J, Yi C H, Gebuhr T, Bullen P J, Robson S C, Strachan T, et al. Nat Genet. 1997;15:21–29. [PubMed] 13. Muller C W, Herrmann B G. Nature (London). 1997;389:884–888. [PubMed] 14. Price M A, Rogers A E, Treisman R. EMBO J. 1995;14:2589–2601. [PubMed] 15. Chen C Y, Schwartz R J. Mol Cell Biol. 1996;16:6372–6384. [PubMed] 16. Molkentin J D, Black B L, Martin J F, Olson E N. Cell. 1995;83:1125–1136. [PubMed] 17. Black B L, Ligon K L, Zhang Y, Olson E N. J Biol Chem. 1996;271:26659–26663. [PubMed] 18. Bamshad M, Lin R C, Law D J, Watkins W C, Krakowiak P A, Moore M E, Franceschini P, Lala R, Holmes L B, et al. Nat Genet. 1997;16:311–315. [PubMed] 19. Chapman D L, Papaioannou V E. Nature (London). 1998;391:695–697. [PubMed] 20. Tada M, Casey E S, Fairclough L, Smith J C. Development (Cambridge, UK). 1998;125:3997–4006. [PubMed] 21. Sauer B. Methods. 1998;14:381–392. [PubMed] 22. Agah R, Frenkel P A, French B A, Michael L H, Overbeek P A, Schneider M D. J Clin Invest. 1997;100:169–179. [PubMed] 23. Chen J, Kubalak S W, Chien K R. Development (Cambridge, UK). 1998;125:1943–1949. [PubMed] 24. Basson C T, Solomon S D, Weissman B, MacRae C A, Poznanski A K, Prieto F, Ruiz de la Fuente S, Pease W E, Levin S E, Holmes L B, et al. Circulation. 1995;91:1326–1329. [PubMed] 25. Wilson G N. Am J Med Genet. 1998;76:297–305. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||
Pediatr Cardiol. 1995 Jul-Aug; 16(4):155-65.
[Pediatr Cardiol. 1995]Pediatr Cardiol. 1995 May-Jun; 16(3):103-13.
[Pediatr Cardiol. 1995]Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2919-24.
[Proc Natl Acad Sci U S A. 1999]EMBO J. 1995 Oct 2; 14(19):4763-72.
[EMBO J. 1995]Bioessays. 1998 Jan; 20(1):9-19.
[Bioessays. 1998]Nature. 1992 Jul 30; 358(6385):427-30.
[Nature. 1992]Development. 1996 Aug; 122(8):2427-35.
[Development. 1996]Genomics. 1998 Jul 1; 51(1):68-75.
[Genomics. 1998]Nat Genet. 1997 Jan; 15(1):21-9.
[Nat Genet. 1997]Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2919-24.
[Proc Natl Acad Sci U S A. 1999]Nature. 1997 Oct 23; 389(6653):884-8.
[Nature. 1997]EMBO J. 1995 Jun 1; 14(11):2589-601.
[EMBO J. 1995]Mol Cell Biol. 1996 Nov; 16(11):6372-84.
[Mol Cell Biol. 1996]Cell. 1995 Dec 29; 83(7):1125-36.
[Cell. 1995]J Biol Chem. 1996 Oct 25; 271(43):26659-63.
[J Biol Chem. 1996]Nat Genet. 1997 Jul; 16(3):311-5.
[Nat Genet. 1997]Nature. 1998 Feb 12; 391(6668):695-7.
[Nature. 1998]Development. 1998 Oct; 125(20):3997-4006.
[Development. 1998]Methods. 1998 Apr; 14(4):381-92.
[Methods. 1998]Development. 1998 May; 125(10):1943-9.
[Development. 1998]Circulation. 1995 Mar 1; 91(5):1326-9.
[Circulation. 1995]Am J Med Genet. 1998 Apr 1; 76(4):297-305.
[Am J Med Genet. 1998]